UTHR (STOCKS)
United Therapeutics Corp
$577.630000
+5.900000 (+1.03%)
Prev close: $571.730000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $25,316.19M
- Employees
- 1,305
- P/E (TTM)
- 20.52
- P/B (TTM)
- 3.52
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $3.18B |
| Benefits Costs and Expenses | $1.47B |
| Cost Of Revenue | $384.40M |
| Costs And Expenses | $1.69B |
| Gross Profit | $2.80B |
| Nonoperating Income/Loss | $221.40M |
| Operating Expenses | $1.31B |
| Selling, General, and Administrative Expenses | $755.80M |
| Research and Development | $550.00M |
| Operating Income/Loss | $1.49B |
| Income/Loss From Continuing Operations After Tax | $1.33B |
| Income/Loss From Continuing Operations Before Tax | $1.71B |
| Income Tax Expense/Benefit | $379.20M |
| Income Tax Expense/Benefit, Current | $281.50M |
| Income Tax Expense/Benefit, Deferred | $97.70M |
| Net Income/Loss | $1.33B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $1.33B |
| Net Income/Loss Available To Common Stockholders, Basic | $1.33B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $30.13 |
| Diluted Earnings Per Share | $27.86 |
| Basic Average Shares | 44,300,000 |
| Diluted Average Shares | 47,900,000 |
| Assets | $7.88B |
| Current Assets | $3.70B |
| Inventory | $183.10M |
| Other Current Assets | $3.52B |
| Noncurrent Assets | $4.18B |
| Fixed Assets | $1.73B |
| Other Non-current Assets | $2.45B |
| Liabilities | $783.80M |
| Current Liabilities | $560.60M |
| Accounts Payable | $7.10M |
| Wages | $105.10M |
| Other Current Liabilities | $448.40M |
| Noncurrent Liabilities | $223.20M |
| Equity | $7.10B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $7.10B |
| Liabilities And Equity | $7.88B |
| Net Cash Flow From Operating Activities | $1.56B |
| Net Cash Flow From Operating Activities, Continuing | $1.56B |
| Net Cash Flow From Investing Activities | -$551.30M |
| Net Cash Flow From Investing Activities, Continuing | -$551.30M |
| Net Cash Flow From Financing Activities | -$1.15B |
| Net Cash Flow From Financing Activities, Continuing | -$1.15B |
| Net Cash Flow | -$140.10M |
| Net Cash Flow, Continuing | -$140.10M |
| Comprehensive Income/Loss | $1.34B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $1.34B |
| Other Comprehensive Income/Loss | $1.34B |
| Other Comprehensive Income/Loss Attributable To Parent | $4.30M |